Alpa Laboratories cash flow

Latest FY26

Cash from operations: ₹10.0cr+41.0% on FY25
Capital spending: ₹4.0cr−65.3% on FY25
Free cash flow: ₹6.0cr−₹4.3 cr in FY25
Cash from financing: ₹2.2cr−₹5.5 cr in FY25

₹ crore except per share

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

Changes in working capital
Adjustments to reconcile profit — non-cash items						FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	—	2.1	0.0	2.0	0.0
	—	0.0	−16.5	0.0	3.4
	—	0.3	0.2	0.4	0.2
	—	−2.2	−2.0	−2.3	−0.1
	—	−0.6	−0.4	−0.2	−0.2
	—	0.0	0.0	−10.0	0.0
	—	11.3	0.0	0.0	0.0
	—	0.9	0.0	0.4	0.0
	—	4.3	−4.0	−1.0	2.8
	—	5.6	−8.2	2.5	−6.5
	—	0.9	20.4	0.0	0.0
	—	−5.9	0.0	−3.7	0.0
	—	−0.9	0.0	0.0	−12.9
	—	3.4	0.0	0.0	0.0
	—	0.0	3.5	−1.3	1.0
Cash from operating activities
	5.9	16.7	25.7	20.7	15.9
	—	19.1	−7.0	−13.4	−12.2
	—	35.8	18.7	7.3	3.8
	—	−23.0	−7.6	0.0	−8.6
	—	2.8	4.1	3.6	0.0
	—	10.0	7.1	3.6	−4.8
Cash from investing activities
	—	4.0	11.4	6.4	1.1
	—	0.0	0.0	0.0	2.5
	—	10.3	3.4	9.5	0.5
	—	0.0	−11.3	0.0	0.0
	—	0.6	0.4	0.2	0.2
	—	2.2	2.0	2.3	0.1
	—	−11.6	−1.1	−13.3	1.2
Cash from financing activities
	—	2.5	0.0	3.7	0.2
	—	0.0	5.2	0.8	3.4
	—	0.3	0.2	0.4	0.2
	—	0.0	0.0	0.0	0.0
	—	2.2	−5.5	2.6	−3.5
	—	0.6	0.5	−7.1	−7.2
	—	0.6	0.5	−7.1	−7.2
	—	—	—	3.1	−4.6
Reference items
	−1.1	3.3	4.8	8.1	7.6
	−1.0%	3.1%	4.2%	7.5%	8.2%
	6.0	6.0	−4.3	−2.7	−6.0
	—	8.2	−9.8	−0.2	—
	₹2.85	₹2.85	−₹2.05	−₹1.30	−₹2.84
	18.31×	—	—	—	—
	—	0.66×	0.36×	0.22×	−0.38×
	—	2.8	4.1	3.6	0.0
	—	0.3	0.2	0.4	0.2

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

ALPA₹52.20

Alpa Laboratories Limited

· Pharma & Health

₹ CrorePeersBALPHARMA KREBSBIO NATCAPSUQ VINEETLAB NECLIFE AAREYDRUGS BIOFILCHEM MANGALAMMcap ₹110 Cr

View

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Adjustments to Reconcile Profit — Non-cash Items
+ Depreciation & Amortisation	0.0	2.0	0.0	2.1	—
+ Impairment Loss / (Reversal)	3.4	0.0	-16.5	0.0	—
+ Finance Costs	0.2	0.4	0.2	0.3	—
+ Interest Income	-0.1	-2.3	-2.0	-2.2	—
+ Dividend Income	-0.2	-0.2	-0.4	-0.6	—
+ Fair Value (Gains) / Losses	0.0	-10.0	0.0	0.0	—
+ Unrealised FX (Gain) / Loss	0.0	0.0	0.0	11.3	—
+ Other Non-cash Items	0.0	0.4	0.0	0.9	—
Changes in Working Capital
+ Inventories	2.8	-1.0	-4.0	4.3	—
+ Trade Receivables — Current	-6.5	2.5	-8.2	5.6	—
+ Trade Payables — Current	0.0	0.0	20.4	0.9	—
+ Trade Payables — Non-current	0.0	-3.7	0.0	-5.9	—
+ Other Current Liabilities	-12.9	0.0	0.0	-0.9	—
+ Other Non-current Liabilities	0.0	0.0	0.0	3.4	—
+ Provisions — Current	1.0	-1.3	3.5	0.0	—
Cash from Operating Activities
Profit Before Tax (per I/S)	15.9	20.7	25.7	16.7	5.9
+ Total Adjustments (incl. Working Capital)	-12.2	-13.4	-7.0	19.1	—
Cash from Operations (pre-tax)	3.8	7.3	18.7	35.8	—
+ Other Inflows / (Outflows) — Operating	-8.6	0.0	-7.6	-23.0	—
+ Income Taxes Paid	0.0	3.6	4.1	2.8	—
Cash from Operating Activities	-4.8	3.6	7.1	10.0	—
Cash from Investing Activities
+ Acq of Fixed Assets (Capex)	1.1	6.4	11.4	4.0	—
+ Disp of Fixed Assets	2.5	0.0	0.0	0.0	—
+ Acq of Investment Property	0.5	9.5	3.4	10.3	—
+ Investment in Partnership Firms / LLPs	0.0	0.0	-11.3	0.0	—
+ Dividends Received — Investing	0.2	0.2	0.4	0.6	—
+ Interest Received — Investing	0.1	2.3	2.0	2.2	—
Cash from Investing Activities	1.2	-13.3	-1.1	-11.6	—
Cash from Financing Activities
+ Proceeds from Borrowings	0.2	3.7	0.0	2.5	—
+ Repayment of Borrowings	3.4	0.8	5.2	0.0	—
+ Interest Paid	0.2	0.4	0.2	0.3	—
+ Other Inflows / (Outflows) — Financing	0.0	0.0	0.0	0.0	—
Cash from Financing Activities	-3.5	2.6	-5.5	2.2	—
Net Changes in Cash (pre-FX)	-7.2	-7.1	0.5	0.6	—
Net Changes in Cash	-7.2	-7.1	0.5	0.6	—
Closing Cash	-4.6	3.1	—	—	—
Reference Items
EBITDA	7.6	8.1	4.8	3.3	-1.1
EBITDA Margin %	8.17	7.45	4.23	3.11	-0.99
Free Cash Flow (CFO − Capex)	-6.0	-2.7	-4.3	6.0	6.0
Free Cash Flow to Equity	—	-0.2	-9.8	8.2	—
Free Cash Flow per Basic Share	-2.84	-1.30	-2.05	2.85	2.85
Price to Free Cash Flow	—	—	—	—	18.31
Cash Flow to Net Income	-0.38	0.22	0.36	0.66	—
Cash Paid for Taxes	0.0	3.6	4.1	2.8	—
Cash Paid for Interest	0.2	0.4	0.2	0.3	—

As filed, sign as filed: a payment tagged as a positive magnitude in the filing stays positive here, so read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown — depth follows the filer, so a thin statement means a thin filing. Total Adjustments is the filer's own grand total of the reconciliation and spans BOTH the non-cash items and the working-capital block; Profit Before Tax plus it equals Cash from Operations (pre-tax). It can be reported when its components are not, so it is never a sum of the rows above it. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.